MEDIPOST has been invited to US ‘Stem cells regenerative medicine congress’ for the first time as a Korean company.

MEDIPOST attended the ‘Stem Cells Regenerative Medicine Congress 2015’ in Washington D.C. on 2~3rd of September and presented on clinical trials and sales strategies for the stem cell treatments.

The congress is an international scientific congress annually held in US from 2008, as a part of Obama’s regenerative medicine industry development plan where major pharmaceutical/bio companies, academia, research centers and public institutions participated.

The executive members of the US corporate of MEDIPOST attended this congress and presented on the experience of commercialization in Korea, clinical status in US and future market extension plans of ‘CARTISTEM^®’, a knee cartilage loss treatment for degenerative osteoarthritis patients, and also discussed on the co-development with US pharmaceutical companies.